Dr Rebecca McQualter appointed COO• Senior experience in big...

Dr Rebecca McQualter appointed COO
• Senior experience in big pharma roles at Novartis, Amgen & GSK
• Doctor of Philosophy in Cell Therapy & Regenerative Medicine from Monash University
• Strong capability in developing commercial partnerships & networks with various
stakeholders
• Senior leadership role as second employee in startup Bioverativ – built multi-million
sales from scratch in one year before the company was acquired
Sydney, Australia, 2 May 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an
Australian leader in cell therapy, is pleased to announce the appointment of Rebecca McQualter,
PhD, to the position of Chief Operating Officer (COO) based in Melbourne.
Dr McQualter will bring senior experience from roles at Novartis, Amgen and GlaxoSmithKline.
Dr McQualter holds a Doctor of Philosophy in Cell Therapy and Regenerative Medicine from Monash
University.
Dr McQualter has an extensive commercial career with exposure to many aspects of international
pharmaceutical operations. Mostly recently, as the Head of Strategic Access at Novartis Australia,
Dr McQualter developed new commercial partnerships, built external networks spanning policy
makers, research institutes and NGOs, and engaged with federal and state government, trade
associations and other stakeholders to implement policy and process improvements. She led the
establishment of key partnerships for Novartis with Telstra Health, Monash University and
Wesfarmers Health.
Prior to her role at Novartis, Dr McQualter was Country Medical Head for Bioverativ ANZ, a $5 billion
Biogen spinout focusing on rare diseases. She played a key role in establishing business processes
and strategies, setting up medical information/pharmacovigilance call centres, and conducting payer
negotiations, aiding in Bioverativ's multi-billion-dollar acquisition by Sanofi in 2018.
She has also previously held leadership roles at Amgen, where she initially worked in Australia
before moving to the United States to take on the role of Senior Marketing Manager for Strategic
Operations in Oncology at Amgen's Thousand Oaks, California office. Further big pharma experience
came at GlaxoSmithKline, where Dr McQualter worked as a Medical Adviser and learning from the
ground up as a Primary Care Sales Representative, where she contributed to launching two major
brands.
Executive Chairman, Paul Hopper, said: "We’re very fortunate to be welcoming Rebecca to Chimeric
as we continue to grow and advance our portfolio of transformative cell therapies. She brings an
excellent array of experience, including having worked alongside Amgen’s Global Head of Oncology
in the US, as well as a commercial focus and dynamic leadership skills that will serve Chimeric well as
it pursues its next phase of growth.”
Dr McQualter will receive annual fixed cash remuneration of A$300,000, with variable remuneration
incentive of up to 40% of the fixed remuneration based on achievement of key performance
indicators agreed to with the Board of Directors. In addition, Dr McQualter will receive 20 million
options in the Company, vesting annually over a four-year period.
Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul
Hopper.
ABOUT CHIMERIC THERAPEUTIC